Pharmaceutical composition for dry powder inhalation and preparation method thereof

A dry powder inhalation composition of bedaquiline with specific excipients and spray-drying techniques addresses the long onset time of oral bedaquiline, enhancing aerosol properties and lung distribution for faster action.

WO2024242630A1PCT designated stage expired Publication Date: 2024-11-28ASG INSPIRATION LABORATORY (SINGAPORE) PTE LTD

Patent Information

Application Number
PCT/SG2024/050334
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Bedaquiline, an antituberculosis drug, has a long onset time due to its oral administration via the gastrointestinal tract, necessitating a pharmaceutical composition for dry powder inhalation that can expedite its onset of action.

Method used

A pharmaceutical composition for dry powder inhalation comprising bedaquiline and pharmacologically acceptable excipients such as amino acids, polysaccharides, phospholipids, and polylactic acid copolymers, which are spray-dried to form finely divided particles with controlled particle sizes and shapes, enhancing aerosol properties and reducing onset time.

Benefits of technology

The composition improves aerosol properties and reduces the onset time of bedaquiline, achieving effective inhalation administration by forming smaller, spherical-shaped particles that prolong flight distance and enhance distribution in the lungs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SG2024050334_28112024_PF_FP_ABST
    Figure SG2024050334_28112024_PF_FP_ABST
Patent Text Reader

Abstract

In some embodiments of the present disclosure, a pharmaceutical composition for dry powder inhalation is provided, including: an active ingredient and a first pharmacologically acceptable excipient. The active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof. In some embodiments of the present disclosure, a method of preparing a pharmaceutical composition for dry powder inhalation is further provided.
Need to check novelty before this filing date? Find Prior Art

Description

PHARMACEUTICAL COMPOSITION FOR DRY POWDER INHALATION AND PREPARATION METHOD THEREOFCROSS - REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to US Provisional Application Serial Number 63 / 504,197, filed May 24, 2023, which is herein incorporated by reference in its entirety.BACKGROUNDField of Invention

[0002] The present disclosure relates to a pharmaceutical composition for dry powder inhalation and a preparation thereof. In particular, the present disclosure relates to a pharmaceutical composition including bedaquiline or a pharmaceutically acceptable salt thereof.Description of Related Art

[0003] Bedaquiline is a diarylquinoline with many characteristics, that makes it an antituberculosis drug. However, it is traditionally administered orally and has long onset time since it needs to be absorbed through the gastrointestinal tract before it can reach the blood circulation.

[0004] Therefore, how to provide a pharmaceutical composition containing bedaquiline and suitable for dry powder inhalation to increase onset time of bedaquiline remains to be solved.SUMMARY

[0005] In one aspect of the present disclosure, a pharmaceutical composition for dry powder inhalation is provided, including: an active ingredient and a first pharmacologically acceptable excipient. The active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof.

[0006] In some embodiments, a weight percentage of the active ingredient is from 50% to 99% and a weight percentage of the first pharmacologically acceptable excipient is from 1% to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0007] In some embodiments, a weight percentage of the amino acid is from 1 % to 20% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0008] In some embodiments, the amino acid includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline or a combination thereof.

[0009] In some embodiments, a weight percentage of the polysaccharide is from 1% to 20% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0010] In some embodiments, the polysaccharide includes chitosan, chitosan salt or a combination thereof.

[0011] In some embodiments, a weight percentage of the phospholipid is from 1 % to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0012] In some embodiments, the phospholipid includes dipalmitoyl phosphatidylcholine, distearoyl phosphatidyl choline or a combination thereof.

[0013] In some embodiments, a weight percentage of the polylactic acid is from 1% to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0014] In some embodiments, a weight percentage of the polylactic acid copolymer is from 1% to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

[0015] In some embodiments, the polylactic acid copolymer includes poly(lactic-co-glycolic acid).

[0016] In some embodiments, the active ingredient and the first pharmacologically acceptable excipient forms a finely divided particle having a particle size of from 50 nm to 6 pm.

[0017] In some embodiments, the finely divided particle is provided in a solid spherical-shaped form, a hollow spherical-shaped form, a solid polyhedron form or a combination thereof.

[0018] In some embodiments, the pharmaceutical composition further includes a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient.

[0019] In some embodiments, a weight percentage of the second pharmacologically acceptable excipient is from 70% to 99.995% based on 100% by weight of the pharmaceutical composition.

[0020] In some embodiments, the second pharmacologically acceptable excipient includes lactose, mannitol or a combination thereof.

[0021] In another aspect of the present disclosure, a method of preparing a pharmaceutical composition for dry powder inhalation, including: dissolving an active ingredient in a first solvent to form a first solution, wherein the active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof; dissolving a first pharmacologically acceptable excipient in a second solvent to form a second solution, wherein the first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof; mixing the first solution and the second solution to form a mixture; and spray drying the mixture to form a finely divided particle.

[0022] In some embodiments, the first solvent and the second solvent include an organic solvent.

[0023] In some embodiments, a weight percentage of the active ingredient and the first pharmacologically acceptable excipient is from 0.5% to 3% based on 100% by weight of the mixture.

[0024] In some embodiments, a weight ratio of the active ingredient and the first pharmacologically acceptable excipient in the mixture is from 1 :1 to 199:1.

[0025] In some embodiments, spray drying the mixture is performed at an outlet temperature of from 35°C to 110°C.

[0026] In some embodiments, an ultrasonic atomization percentage of the mixture at the step of spray drying the mixture is from 25% to 85%.

[0027] In some embodiments, the method further includes mixing the finely divided particle with a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient.

[0028] In some embodiments, the second pharmacologically acceptable excipient includes a first size group, a second size group or a combination thereof, wherein a volume-basis particle size distribution of the first size group is different from a volume-basis particle size distribution of the second size group.

[0029] In some embodiments, a particle size D50 of the first size group is from 5 pm to 50 pm and a particle size D50 of the second size group is from 30 pm to 125 pm.

[0030] In some embodiments, the method further includes mixing the finely divided particle with a flavoring agent.BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to make the above-mentioned and other objects, features, advantages and embodiments of the present disclosure more clearly understood, descriptions of accompanying drawings are as follows:

[0032] Fig. 1 illustrates a flow chart of a method of preparing a pharmaceutical composition for dry powder inhalation in some embodiments of the present disclosure.

[0033] Fig. 2A and Fig. 2B respectfully illustrate bedaquiline without spray drying and finely divided particles under the field of an electron microscope.

[0034] Fig. 3A and Fig. 3B illustrates finely divided particles under the field of an electron microscope, in which bedaquiline in Fig. 3A is mixed with dipalmitoyl phosphatidylcholine (DPPC) before spray drying, and bedaquiline in Fig. 3B is mixed with distearoyl phosphatidyl choline (DSPC) before spray drying.

[0035] Fig. 4 illustrates finely divided particles under the field of an electron microscope, in which bedaquiline is mixed with poly(lactic-co-glycolic acid) (PLGA) before spray drying.

[0036] Fig. 5 illustrates aerosol properties of group BED only, group BED+DSPC and group BED+DSPC+Lac using Next Generation Impactor (NGI).DETAILED DESCRIPTION

[0037] In order that the present disclosure is described in detail and completeness, implementation aspects and specific embodiments of the present disclosure with illustrative description are presented, but those are not the only form for implementation or plucuse of the specific embodiments of the present disclosure. The embodiments disclosed herein may be combined or substituted with each other in an advantageous manner, and other embodiments may be added to an embodiment without further description. In the following description, numerous specific details will be described in detail in order to enable the reader to fully understand the following embodiments. However, the embodiments of the present disclosure may be practiced without these specific details.

[0038] Although a series of operations or steps are described below to illustrate the method disclosed herein, the order of the operations or steps is not to be construed as limiting. For example, certain operations or steps may be performedin a different order and / or concurrently with other steps. In addition, not all illustrated operations, steps, and / or features are required to implement embodiments of the present disclosure. Moreover, each of the operations or steps described herein may include a plurality of sub-steps or actions.

[0039] In this description, unless the context specifically dictates otherwise, "a" and "the" may mean a single or a plurality. It will be further understood that "comprise", "include", "have", and similar terms as used herein indicate described features, regions, integers, steps, operations, elements and / or components, but not exclude other features, regions, integers, steps, operations, elements, components and / or groups.

[0040] As used herein, "drug" or "active ingredient" refers to bedaquiline or its pharmaceutically acceptable salt thereof, including but not limited to salts, esters, complexes, chelating agents, cage compounds, racemates, mirror image isomers, or the like.

[0041] As used herein, "pharmacologically acceptable excipient” refers to pharmaceutical additives without pharmacological activity and used in pharmaceutical compositions according to different purposes and functions.

[0042] The main purpose of the present disclosure is to provide a pharmaceutical composition for dry powder inhalation with reduced particle sizes and some specified shapes, thereby increasing aerosol property (such as increasing fine particle fraction (FPF)) for meeting the requirements for inhalation administration and reducing onset time.

[0043] Please refer to Fig. 1 , representing a flow chart of a method 100 of preparing a pharmaceutical composition for dry powder inhalation in some embodiments of the present disclosure, including step S110, step S120, stepS130 and step S140. It should be emphasized that by mixing a first pharmacologically acceptable excipient with bedaquiline in the mixture and then spray drying the mixture, the shape and the particle size of finely divided particles can be regulated, so that the aerosol property and onset time of the finely divided particle can be improved.

[0044] First of all, refer to step S110, dissolving an active ingredient in a first solvent to form a first solution, in which the active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof.

[0045] In some embodiments, the first solution includes an organic solvent for easily dissolving the active ingredient, such as ethanol, methanol, methylene chloride, ethyl acetate, acetonitrile, acetone or a combination thereof. In some other embodiments, the first solution includes water.

[0046] Please refer to step S120, dissolving a first pharmacologically acceptable excipient in a second solvent to form a second solution, in which the first pharmacologically acceptable excipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof.

[0047] In some embodiments, the second solution includes an organic solvent for easily dissolving the first pharmacologically acceptable excipient, such as ethanol, methanol, methylene chloride, ethyl acetate, acetonitrile, acetone or a combination thereof. In some embodiments, the second solution is the same as the first solution.

[0048] In some embodiments, amino acid includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline or a combination thereof. In some embodiments,polysaccharide includes chitosan, chitosan salt or a combination thereof. In some embodiments, phospholipid includes dipalmitoyl phosphatidylcholine (DPPC), distearoyl phosphatidyl choline (DSPC) or a combination thereof. In some embodiments, polylactic acid copolymer includes poly(lactic-co-glycolic acid) (PLGA).

[0049] Please refer to step S130, mixing the first solution and the second solution to form a mixture.

[0050] In some embodiments, a weight percentage of the active ingredient and the first pharmacologically acceptable excipient is from 0.5% to 3% by weight of the mixture, such as, 0.5%, 1%, 1.5%, 2%, 2.5%, 3% or any value between any interval of the abovementioned values. If the weight percentage is too low, the production yield for spray drying is limited. If the weight percentage is too high, the efficiency of spray drying is limited since the mixture may be uneven and too viscose to be spray dried. In some embodiments, a weight ratio of the active ingredient and the first pharmacologically acceptable excipient in the mixture is from 1 :1 to 199:1 , such as 1:1 , 10:1 , 20:1, 30:1 , 40:1 , 50:1 , 60:1 , 70:1, 80:1 , 90:1 , 100:1 , 110:1 , 120:1 , 130:1, 140:1 , 150:1 , 160:1 , 170:1, 180:1 , 190:1, 199:1 or any value between any interval of the abovementioned values. If the weight ratio is too low, the yield of the active ingredient contained in the finely divided particle after spray drying is limited. If the weight ratio is too high, the aerosol property is reduced since the finely divided particle is hardly regulated by the first pharmacologically acceptable excipient.

[0051] Please refer to step S140, spray drying the mixture to form a finely divided particle.

[0052] In some embodiments, spray drying the mixture is performed at an outlet temperature of from 35°C to 110°C, such as 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 110°C or any value between any interval of the abovementioned values. If the outlet temperature is too low, the sprayed droplets are too large, the particle size of the sprayed particles tends to be larger, and the shape of the sprayed particles will be difficult to maintain in a spherical-shaped form. If the outlet temperature is high, the structure of the active ingredient or the pharmacologically acceptable excipients may be changed, thereby influencing the functions. In some embodiments, an ultrasonic atomization percentage of the mixture at the step of spray drying the mixture is from 25% to 85%, such as 25%, 40%, 55%, 70%, 85% or any value between any interval of the abovementioned values.

[0053] In some embodiments, the finely divided particle can be packed into capsules, aluminum foil blisters, and drug storage tanks in dry powder inhalation devices for subjects in need to inhale.

[0054] In some embodiments, the method 100 further includes mixing the finely divided particle with a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient. It’s noted that the addition of the second pharmacologically acceptable excipient increases the aerosol property, prolonging the flight distance of the finely divided particle and increase the distribution ratio in lungs after inhalation administration.

[0055] In some embodiments, the second pharmacologically acceptable excipient includes lactose, mannitol or a combination thereof.

[0056] In some embodiments, the second pharmacologically acceptable excipient includes a first size group, a second size group or a combination thereof, in whicha volume-basis particle size distribution of the first size group is different from a volume-basis particle size distribution of the second size group. In some embodiments, a particle size D50 of the first size group is from 5 pm to 50 pm (5 pm, 10 pm, 20 pm, 30 pm, 40 pm, 50 pm or any value between any interval of the abovementioned values) and a particle size D50 of the second size group is from 30 pm to 125 pm (30 pm, 40 pm, 50 pm, 60 pm, 70 pm, 80 pm, 90 pm, 100 pm, 110 pm, 125 pm or any value between any interval of the abovementioned values).

[0057] In some embodiments, a weight ratio of the second pharmacologically acceptable excipient and the finely divided particle is from 70:30 to 99.995:0.005, such as 70:30, 80:20, 90:10, 99.995:0.005 or any value between any interval of the abovementioned values. If the weight ratio of the second pharmacologically acceptable excipient is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight ratio of the second pharmacologically acceptable excipient is too low, the improvement of the aerosol property is limited.

[0058] In some embodiments, the method 100 further includes mixing the finely divided particle with a flavoring agent (such as menthol or natural flavors tasting like lemon, strawberry, orange, etc.) at a weight percentage of less than 1% to reduce bitter taste when inhalation.

[0059] A pharmaceutical composition for dry powder inhalation is provided in some embodiments, including: an active ingredient and a first pharmacologically acceptable excipient. The active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmacologically acceptableexcipient includes amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof.

[0060] Through the use of the first pharmacologically acceptable excipient, the shape and the particle size of the pharmaceutical composition through spray dried can be regulated, so that the aerosol property of the pharmaceutical composition can be improved.

[0061] In some embodiments, a viscosity of the first pharmacologically acceptable excipient is lower than 3 dl / g, such as from 0.1 dl / g to 3 dl / g. If the viscosity is too high, the first pharmacologically acceptable excipient is hardly spray dried and the particle size of the finely divided particle is too big to meet the requirement of inhalation administration.

[0062] In some embodiments, a weight percentage of the active ingredient is from 50% to 99% (such as 50%, 60%, 70%, 80%, 90%, 95%, 99% or any value between any interval of the abovementioned values), and a weight percentage of the first pharmacologically acceptable excipient is from 1% to 50% (such as 1%, 10%, 20%, 30%, 40%, 50% or any value between any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of the active ingredient is too low or the weight percentage of the first pharmacologically acceptable excipient is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of the active ingredient is too high or the weight percentage of the first pharmacologically acceptable excipient is too low, the aerosol property of the pharmaceutical composition is reduced.

[0063] In some embodiments, a weight percentage of amino acid is from 1% to 20% (such as 1 %, 5%, 10%, 15%, 20% or any value between any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of amino acid is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of amino acid is too low, the aerosol property of the pharmaceutical composition is reduced.

[0064] In some embodiments, a weight percentage of polysaccharide is from 1% to 20% (such as 1%, 5%, 10%, 15%, 20% or any value between any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of polysaccharide is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of polysaccharide is too low, the aerosol property of the pharmaceutical composition is reduced.

[0065] In some embodiments, a weight percentage of phospholipid is from 1 % to 50% (such as 1 %, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any value between any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of phospholipid is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of phospholipid is too low, the aerosol property of the pharmaceutical composition is reduced.

[0066] In some embodiments, a weight percentage of polylactic acid (PLA) is from 1% to 50% (such as 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any valuebetween any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of PLA is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of PLA is too low, the aerosol property of the pharmaceutical composition is reduced.

[0067] In some embodiments, a weight percentage of polylactic acid copolymer (such as PLGA) is from 1% to 50% (such as 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any value between any interval of the abovementioned values) based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient. If the weight percentage of polylactic acid copolymer is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of polylactic acid copolymer is too low, the aerosol property of the pharmaceutical composition is reduced.

[0068] In some embodiments, the active ingredient and the first pharmacologically acceptable excipient forms a finely divided particle having a particle size of from 50 nm to 6 pm, such as 50 nm, 100 nm, 500 nm, 1 pm, 2 pm, 3 pm, 4 pm, 5 pm, 6 pm or any value between any interval of the abovementioned values. It is noted that the particle size of the finely divided particle is smaller than the active ingredient without spray drying. Therefore, the requirement of the particle size for inhalation to lungs will be fulfilled.

[0069] In some embodiments, the finely divided particle is provided in a solid spherical-shaped form, a hollow spherical-shaped form, a solid polyhedron form or a combination thereof. The shape of the finely divided particle can increase theflight distance of the finely divided particles and enhance the distribution ratio in lungs while administration.

[0070] In some embodiments, the pharmaceutical composition further includes a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient, such as lactose, mannitol or a combination thereof. The addition of the second pharmacologically acceptable excipient can further increase the flight distance of the finely divided particles and enhance the distribution ratio in lungs while administration.

[0071] In some embodiments, a weight percentage of the second pharmacologically acceptable excipient is from 70% to 99.995% based on 100% by weight of the pharmaceutical composition, such as 70%, 80%, 90%, 95%, 99.995% or any value between any interval of the abovementioned values. If the weight percentage of the second pharmacologically acceptable excipient is too high, the active ingredient provided in a specific unit of pharmaceutical composition is limited. If the weight percentage of the second pharmacologically acceptable excipient is too low, the improvement of the aerosol property is limited.

[0072] In some embodiments, the pharmaceutical composition further includes a third pharmacologically acceptable excipient for regulating the characteristics, such as aerodynamics, flavor, etc.

[0073] It should be understood that the above-described embodiments and the following examples are given by way of illustration, not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the present description.

[0074] For clarifying the pharmaceutical composition for dry powder inhalation and preparation method thereof, several examples and functional testes are described below in sequence.

[0075] Example 1 -Preparation Method of Pharmaceutical Composition for Dry Powder Inhalation and Physical Properties

[0076] 1. First Pharmacologically Acceptable Excipients Added before Spray Drying

[0077] (1) Amino Acid

[0078] Step a: Bedaquiline and leucine were respectively dissolved in ethanol and then mixed together to form a mixture according to the formulation listed in Table 1.

[0079] Table 1

[0080] Step b: The mixture obtained in step a was spray dried at an outlet temperature of 80°C and with an atomization ratio of 65% to form finely divided particles.

[0081] Compared with other conditions in Table 1 , the finely divided particles prepared by the condition of the weight ratio of 95:5 and the concentration of1 .0% achieved the better efficiency of mixing and spray drying and were selected for the following physical observations.

[0082] Shape of Finely Divided Particles

[0083] Appearances of bedaquiline in different preparation steps were observed under the field of an electron microscope, please refer to Fig. 2A and Fig. 2B for the results, in which bedaquiline in Fig. 2A was observed at the step before step b (not spray dried), and bedaquiline in Fig. 2B was observed at the step after step b (spray dried).

[0084] Fig. 2A represented the shape of bedaquiline before step b (not spray dried) was irregular and fragmented form. Fig. 2B represented the shape of finely divided particles (spray dried) was spherical-shaped form.

[0085] Particle Size

[0086] The particle size (D10, D50, and D90) of the finely divided particles was analyzed after 5 repeated tests and summarized in Table 2.

[0087] Table 2Note: D10 referred to the particle size corresponding to the cumulative frequency of 10%. D50 referred to the particle size corresponding to the cumulative frequency of 50%. D90 referred to the particle size corresponding to the cumulative frequency of 90%.

[0088] It was observed that the particle size of the finely divided particles was smaller than 2 pm, smaller than bedaquiline that was not spray dried (not shown in Table 2).

[0089] (2) Phospholipid

[0090] Step a: Bedaquiline and DPPC (Mw=744 g / mol), or bedaquiline and DPSC (Mw=790 g / mol), were respectively dissolved in ethanol and then mixed together to form a mixture according to the formulation listed in Table 3.

[0091] Table 3

[0092] Step b: The mixture obtained in step a was spray dried at an outlet temperature of 80°C and with an atomization ratio of 65% to form finely divided particles.

[0093] Compared with other conditions in Table 3, the finely divided particles prepared by the condition of the weight ratio of 99:1 and the concentration of 2% achieved the finely divided particles with the smaller particle size and more spherical-shaped form and were selected for the following physical observations.

[0094] Shape of Finely Divided Particles

[0095] Appearances of bedaquiline (DPPC or DPSC was used as first pharmacologically acceptable excipient) after spray drying were observed under the field of an electron microscope, please refer to Fig. 3A and Fig. 3B for the results. Fig. 3A and Fig. 3B were represented the shapes of finely divided particles, in which bedaquiline in Fig. 3A was mixed with DPPC before spray drying, and bedaquiline in Fig. 3B was mixed with DSPC before spray drying.

[0096] Fig. 3A and Fig. 3B represented the shapes of finely divided particles were spherical-shaped form or polyhedron form (such as golf ball type that is solid polyhedron form with multiple recesses in the surface).

[0097] Particle Size

[0098] The particle size (D10, D50, and D90) of the finely divided particles that bedaquiline was mixed with DPPC was analyzed after 5 repeated tests and summarized in Table 4 (DPPC).

[0099] Table 4 (DPPC was added)

[0100] The particle size (D10, D50, and D90) of the finely divided particles that bedaquiline was mixed with DSPC was summarized in Table 5 (DSPC).

[0101] Table 5 (DSPC was added)

[0102] It was observed that the particle size of the finely divided particles was smaller than 5 pm, smaller than bedaquiline that was not spray dried (not shown in Table 4 and 5).

[0103] (3) Polylactic Acid or Polylactic Acid Copolymer

[0104] Step a: Bedaquiline and poly(lactic-co-glycolic acid) (PLGA) with viscosity of from 0.16 dl / g to 0.24 dl / g were respectively dissolved in acetone and then mixed together to form a mixture according to the formulation listed in Table 6.

[0105] Table 6

[0106] Step b: The mixture obtained in step a was spray dried at an outlet temperature of 45°C and with an atomization ratio of 65% to form finely divided particles.

[0107] Compared with other conditions in Table 6, the finely divided particles prepared by the condition of the weight ratio of 95:5 and the concentration of 2.0% achieved the finely divided particles with the smaller particle size and more spherical-shaped form and were selected for the following physical observations.

[0108] Shape of Finely Divided Particles

[0109] Appearances of finely divided particles (PLGA was used as pharmacologically acceptable excipient) were observed under the field of an electron microscope, please refer to Fig. 4 for the result.

[0110] Fig. 4 represented the shape of finely divided particles was sphericalshaped form or polyhedron form (such as golf ball type).

[0111] Particle Size

[0112] The particle size (D10, D50, and D90) of the finely divided particles was analyzed after 5 repeated tests and summarized in Table 7.

[0113] Table 7

[0114] It was observed that the particle size of the finely divided particles was smaller than 5.5 pm, smaller than bedaquiline that was not spray dried (not shown in Table 7).

[0115] 2. Second Pharmacologically Acceptable Excipients Added after Spray Drying

[0116] Lactose or Mannitol

[0117] Lactose or mannitol with two groups of particle sizes was added to a high- efficiency mixer and mixed with the finely divided particles obtained by the abovementioned point 1. (2) that DPSC was used as the first pharmacologically acceptable excipient and the condition of the weight ratio of 99:1 and theconcentration of 2% was selected, in which the mixing ratio of the second pharmacologically acceptable excipient (lactose or mannitol) and bedaquiline was conducted according to Table 8 (lactose) or Table 9 (mannitol).

[0118] Table 8

[0119] Table 9

[0120] Aerosol Property

[0121] For compare the aerosol property of the finely divided particles prepared by directly spray drying, adding first pharmacologically acceptable excipient before spray drying, or adding first pharmacologically acceptable excipient before spray drying and second pharmacologically acceptable excipient after spray drying, the finely divided particles of group BED only, group BED+DSPC and group BED+DSPC+Lac were provided for detecting aerosol property according to cascade impaction (Cl) using Next Generation Impactor (NGI) (brand: Copley Scientific, device name: Model 170) at a flow rate of 60L / min. Group BED onlywas prepared by directly spray drying bedaquiline, group BED+DSPC was prepared by adding first pharmacologically acceptable excipient, DSPC, before spray drying, and group BED+DSPC+Lac was prepared by adding first pharmacologically acceptable excipient, DSPC, before spray drying and adding second pharmacologically acceptable excipient, lactose, after spray drying.

[0122] Please refer to Fig. 5 and Table 10 (the data summarized according to Fig.5) for the results, in which fine particle fraction (FPF) was the percentage of the cumulative deposition content of the finely divided particles smaller than 5 pm to the total output content of the finely divided particles, which reflected the effective deposition ratio of the finely divided particles in the lungs.

[0123] Fig. 5 represented that compared with group BED only, the finely divided particles of group BED+DSPC and group BED+DSPC+Lac were less distributed in the stages of Induction Port (IP) and Preseparator (the relatively shorter flight distance), and the finely divided particles of group BED+DSPC and group BED+DSPC+Lac were increasingly distributed in the following stages, such as the stages of S2 to S8, indicating the relatively longer flight distance was achieved. That is, compared with group BED only, group BED+DSPC and group BED+DSPC+Lac demonstrated the longer flight distance.

[0124] Furthermore, compared with group BED+DSPC, it was observed that the finely divided particles of group BED+DSPC+Lac were increasingly distributed in the stages of S3 to S6, the stages that required the relatively longer flight distance. That is, compared with group BED+DSPC, group BED+DSPC+Lac further demonstrated the longer flight distance.

[0125] Table 10note: MMAD was mass median aerodynamic diameter.

[0126] Table 10 represented group BED+DSPC and group BED+DSPC+Lac performed higher FPF and smaller MMAD than group BED only, and group BED+DSPC+Lac performed higher FPF and smaller MMAD than group BED+DSPC.

[0127] Therefore, Fig. 5 and Table 10 indicated that the ranking of the flight distance (long to short) among the finely divided particles of the three groups was (1) the finely divided particles prepared by adding first pharmacologically acceptable excipient before spray drying and second pharmacologically acceptable excipient after spray drying, (2) the finely divided particles prepared by adding first pharmacologically acceptable excipient before spray drying, and (3) the finely divided particles prepared by directly spray drying in order. That is, according to the data above, it was demonstrated that the finely divided particles prepared by adding first pharmacologically acceptable excipient or prepared by adding first pharmacologically acceptable excipient and second pharmacologically acceptable excipient achieved the higher distribution ratio in lungs than the finely divided particles prepared by directly spray drying.

[0128] Furthermore, please refer back to Fig. 2B, Fig. 3A, Fig. 3B and Fig. 4 and refer to Fig. 5 and Table 10, together, it was also noted that the shapes of finelydivided particles when bedaquiline was at least mixed with first pharmacologically acceptable excipient before spray drying achieved the longer flight distance and the higher distribution ratio of the finely divided particles in lungs while administration.

[0129] Example 2-Animal Study of Comparative Test

[0130] For observing the absorption efficiency, Sprague-Dawley rats (SD rates) were selected as the experimental animals and the grouping of the animal study was conducted according to Table 11 , in which the finely divided particles of group BED+Leu were obtained in point 1 (1) of Example 1 (the condition of the weight ratio of 95:5 and the concentration of 1.0%) and group BED+DSPC was obtained in point 1 (2) of Example 1 (the condition of the weight ratio of 99:1 and the concentration of 2%) .

[0131] Table 11

[0132] 0.2-0.3 mL / rat of the blood samples of the rats in groups 1 and 2 were collected from the submandibular vein or anterior vena cava of rats before administration and at 2 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 10 h, 24 h, and 48 h after administration. The blood samples of the rats in group 3 werecollected similar to the collecting method of groups 1 and 2 before administration and at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 10 h, 24 h, and 48 h after administration. Each blood sample was mixed and anticoagulated with heparin sodium (at least 40U of heparin sodium anticoagulated 1mL of blood). The anticoagulated blood was then centrifuged at 2000g for 10 min at 4°C to collect the centrifuged plasma, and then the centrifuged plasma was transferred to a new tube to analyze or for storage below -30°C until analysis.

[0133] Furthermore, pharmacokinetic parameters of bedaquiline were analyzed by the blood samples of three groups and summarized in Table 12.

[0134] Table 12Note: T1 / 2 was half time of bedaquiline in blood, Cmax was maximum plasma concentration, and Tmax was time to reach Cmax.

[0135] Table 12 represented that compared with group 3, groups 1 and 2 had less Tmax (about 5min), indicating less time was required to reach Cmax. That is, the onset time of groups 1 and 2 (inhalation) were quicker than group 3 (orally administration).

[0136] Although the disclosure has been disclosed in the above embodiments, it is not intended to limit the disclosure, and it is to be understood that those skilled in the art can make various changes and modifications without departing from the spirit and scope of the disclosure. The scope of protection of the present disclosure is subject to the definition of the scope of claims.

Claims

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for dry powder inhalation comprising: an active ingredient, wherein the active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof; and a first pharmacologically acceptable excipient, comprising amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof.

2. The pharmaceutical composition of claim 1 , wherein a weight percentage of the active ingredient is from 50% to 99% and a weight percentage of the first pharmacologically acceptable excipient is from 1 % to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

3. The pharmaceutical composition of claim 1 , wherein a weight percentage of the amino acid is from 1% to 20% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

4. The pharmaceutical composition of claim 1 , wherein the amino acid comprises glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline or a combination thereof.

5. The pharmaceutical composition of claim 1 , wherein a weight percentage of the polysaccharide is from 1% to 20% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

6. The pharmaceutical composition of claim 1 , wherein the polysaccharide comprises chitosan, chitosan salt or a combination thereof.

7. The pharmaceutical composition of claim 1 , wherein a weight percentage of the phospholipid is from 1% to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

8. The pharmaceutical composition of claim 1 , wherein the phospholipid comprises dipalmitoyl phosphatidylcholine, distearoyl phosphatidyl choline or a combination thereof.

9. The pharmaceutical composition of claim 1 , wherein a weight percentage of the polylactic acid is from 1% to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

10. The pharmaceutical composition of claim 1 , wherein a weight percentage of the polylactic acid copolymer is from 1 % to 50% based on 100% by weight of the active ingredient and the first pharmacologically acceptable excipient.

11. The pharmaceutical composition of claim 1, wherein the polylactic acid copolymer comprises poly(lactic-co-glycolic acid).

12. The pharmaceutical composition of claim 1, wherein the active ingredient and the first pharmacologically acceptable excipient forms a finely divided particle having a particle size of from 50 nm to 6 pm.

13. The pharmaceutical composition of claim 12, wherein the finely divided particle is provided in a solid spherical-shaped form, a hollow sphericalshaped form, a solid polyhedron form or a combination thereof.

14. The pharmaceutical composition of claim 1 , further comprising a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient.

15. The pharmaceutical composition of claim 14, wherein a weight percentage of the second pharmacologically acceptable excipient is from 70% to 99.995% based on 100% by weight of the pharmaceutical composition.

16. The pharmaceutical composition of claim 14, wherein the second pharmacologically acceptable excipient comprises lactose, mannitol or a combination thereof.

17. A method of preparing a pharmaceutical composition for dry powder inhalation, comprising:dissolving an active ingredient in a first solvent to form a first solution, wherein the active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof; dissolving a first pharmacologically acceptable excipient in a second solvent to form a second solution, wherein the first pharmacologically acceptable excipient comprises amino acid, polysaccharide, phospholipid, polylactic acid, polylactic acid copolymer, or a combination thereof; mixing the first solution and the second solution to form a mixture; and spray drying the mixture to form a finely divided particle.

18. The method of claim 17, wherein the first solvent and the second solvent comprise an organic solvent.

19. The method of claim 17, wherein a weight percentage of the active ingredient and the first pharmacologically acceptable excipient is from 0.5% to 3% based on 100% by weight of the mixture.

20. The method of claim 17, wherein a weight ratio of the active ingredient and the first pharmacologically acceptable excipient in the mixture is from 1 :1 to 199:1.

21. The method of claim 17, wherein spray drying the mixture is performed at an outlet temperature of from 35°C to 110°C.

22. The method of claim 17, wherein an ultrasonic atomization percentage of the mixture at the step of spray drying the mixture is from 25% to 85%.

23. The method of claim 17, further comprising mixing the finely divided particle with a second pharmacologically acceptable excipient different from the first pharmacologically acceptable excipient.

24. The method of claim 23, wherein the second pharmacologically acceptable excipient comprises a first size group, a second size group or a combination thereof, wherein a volume-basis particle size distribution of the first size group is different from a volume-basis particle size distribution of the second size group.

25. The method of claim 24, wherein a particle size D50 of the first size group is from 5 pm to 50 pm and a particle size D50 of the second size group is from 30 pm to 125 pm.

26. The method of claim 17, further comprising mixing the finely divided particle with a flavoring agent.

Citation Information

Patent Citations

  • Dry powder compositions of bedaquiline and salts and methods of use thereof

    WO2023150747A1

Cited By

  • Pharmaceutical formulation of erdosteine and preparation method therefor

    WO2025254587A1